Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

A Dose Of Government Would Be Bad Medicine


Readers Report

A DOSE OF GOVERNMENT WOULD BE BAD MEDICINE

Lost in Joan O'C. Hamilton's commentary on U.S. biotechnology is any mention of foreign competition ("A little dose of government won't kill biotech," Science & Technology, Feb. 28).

Biotech firms promise U.S. leadership in a vital industry if they can continue to attract venture capital.

Some years back, the French government imposed "value pricing" on prescription drugs. Investors took their money elsewhere, and research was curtailed. France's pharmaceutical industry, especially small biotech firms, never recovered. The share of the global market in new drugs for French companies fell from 18% to less than 8% in a few years, something to consider the next time someone endorses a government review board to oversee drug prices.

Mary L. Walker

President

San Diego Biocommerce Assn.

San Diego


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus